Tweak/Fn14 system is involved in rhabdomyolysis-induced acute kidney injury
Author
Guerrero-Hue, Melania
Vallejo-Mudarra, Mercedes
García-Caballero, Cristina
Córdoba-David, Gina Marcela
Palomino-Antolín, Alejandra
Herencia, Carmen
Vendrell-Casana, Beatriz
Rubio-Navarro, Alfonso
Egido, J.
Blanco-Colio, Luis M.
Moreno, Juan Antonio
Publisher
ElsevierDate
2023Subject
RhabdomyolysisAcute kidney injury
TWEAK
Fn14
Myoglobin
Inflammation
Fibrosis
METS:
Mostrar el registro METSPREMIS:
Mostrar el registro PREMISMetadata
Show full item recordAbstract
Background
Rhabdomyolysis is a severe clinical syndrome associated to acute kidney injury (AKI) and chronic kidney disease (CKD). TWEAK/Fn14 signaling axis regulates renal inflammation and tubular cell death. However, the functional role of TWEAK/Fn14 in rhabdomyolysis remains unknown.
Methods
Rhabdomyolysis was induced in wild-type, TWEAK- and Fn14-deficient mice or mice treated with TWEAK blocking antibody. Renal injury, inflammation, fibrosis and cell death were assessed. Additionally, we performed in vivo and in vitro studies to explore the possible signalling pathways involved in Fn14 regulation.
Findings
Fn14 renal expression was increased in mice with rhabdomyolysis, correlating with decline of renal function. Mechanistically, myoglobin (Mb) induced Fn14 expression via ERK and p38 pathway, whereas Nrf2 activation diminished Mb-mediated Fn14 upregulation in cultured renal cells. TWEAK or Fn14 genetic depletion ameliorated rhabdomyolysis-associated loss of renal function, histological damage, tubular cell death, inflammation, and expression of both tubular and endothelial injury markers. Deficiency of TWEAK or Fn14 also decreased long-term renal inflammation and fibrosis in mice with rhabdomyolysis. Finally, pharmacological treatment with a blocking TWEAK antibody diminished the expression of acute renal injury markers and cell death and lessened residual kidney fibrosis and chronic inflammation in rhabdomyolysis.
Interpretation
TWEAK/Fn14 axis participates in the pathogenesis of rhabdomyolysis-AKI and subsequent AKI-CKD transition. Blockade of this signaling pathway may represent a promising therapeutic strategy for reducing rhabdomyolysis-mediated renal injury.

